George Frangeskides, Exec-Chair at Alba Mineral Resources, discusses grades at the Clogau Gold Mine. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Regulatory News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 137.50
Bid: 135.00
Ask: 140.00
Change: 0.00 (0.00%)
Spread: 5.00 (3.704%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 137.50
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Faron to Present at Redeye Fight Cancer Seminar

17 Jan 2022 07:00

RNS Number : 5603Y
Faron Pharmaceuticals Oy
17 January 2022
 

Faron Pharmaceuticals Ltd.

("Faron")

 

Faron to Present at the Redeye Fight Cancer - Outlook 2022 Seminar

 

Press Release, January 17, 2022 at 02:00 AM (EDT) / 07:00 AM (GMT) / 09:00 AM (EET)

 

TURKU, FINLAND / BOSTON, MA - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation, today announced that Dr. Markku Jalkanen, Chief Executive Officer of Faron, will participate in the Redeye Fight Cancer - Outlook 2022 Seminar, taking place on January 20, 2022.

 

Dr. Jalkanen will provide a presentation on Faron and participate in a panel discussion focused on the future of immuno-oncology. Event registration details can be found on the "Investors" section on Faron's website at https://www.faron.com/investors.

 

For more information please contact:

 

Media Contact

Faron Pharmaceuticals

Eric Van Zanten

Head of Communications

eric.vanzanten@faron.com

Investor.relations@faron.com

+1 (610) 529-6219

 

Investor Contact

Stern Investor Relations

Julie Seidel

julie.seidel@sternir.com

Phone: +1 (212) 362-1200

 

Cairn Financial Advisers LLP, Nomad

Sandy Jamieson, Jo Turner, Mark Rogers

Phone: +44 (0) 207 213 0880

 

Peel Hunt LLP, Broker

Christopher Golden, James Steel

Phone: +44 (0) 20 7418 8900

 

Sisu Partners Oy, Certified Adviser on Nasdaq First North

Juha Karttunen

Phone: +358 (0)40 555 4727

Jukka Järvelä

Phone: +358 (0)50 553 8990

 

Consilium Strategic Communications

Mary-Jane Elliott, David Daley, Lindsey Neville

Phone: +44 (0)20 3709 5700

E-mail: faron@consilium-comms.com

 

 

About Bexmarilimab

Bexmarilimab is Faron's wholly-owned, investigative precision immunotherapy with the potential to provide permanent immune stimulation for difficult-to-treat cancers through targeting myeloid cell function. A novel anti-Clever-1 humanised antibody, bexmarilimab targets Clever-1 positive (Common Lymphatic Endothelial and Vascular Endothelial Receptor 1) tumour associated macrophages (TAMs) in the tumour microenvironment, converting these highly immunosuppressive M2 macrophages to immune stimulating M1 macrophages. In mouse models, bexmarilimab has successfully blocked or silenced Clever-1, activating antigen presentation and promoting interferon gamma secretion by leukocytes. Additional pre-clinical studies have proven that Clever-1, encoded by the Stabilin-1 or STAB-1 gene, is a major source of T cell exhaustion and involved in cancer growth and spread. Observations from clinical studies to date indicate that Clever-1 has the capacity to control T cell activation directly, suggesting that the inactivation of Clever-1 as an immune suppressive molecule could be more broadly applicable and more important than previously thought. As an immuno-oncology therapy, bexmarilimab has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. Beyond immuno-oncology, it offers potential in infectious diseases, vaccine development and more.

 

About Faron Pharmaceuticals Ltd

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs caused by dysfunction of our immune system. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology, organ damage and bone marrow regeneration. Bexmarilimab, a novel anti-Clever-1 humanized antibody, is its investigative precision immunotherapy with the potential to provide permanent immune stimulation for difficult-to-treat cancers through targeting myeloid function. Currently in Phase I/II clinical development as a potential therapy for patients with untreatable solid tumors, bexmarilimab has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. Traumakine is an investigational intravenous (IV) interferon beta-1a therapy for the treatment of acute respiratory distress syndrome (ARDS) and other ischemic or hyperinflammatory conditions. Traumakine is currently being evaluated in global trials as a potential treatment for hospitalized patients with COVID-19 and with the 59th Medical Wing of the US Air Force and the US Department of Defense for the prevention of multiple organ dysfunction syndrome (MODS) after ischemia-reperfusion injury caused by a major trauma. Faron is based in Turku, Finland. Further information is available at www.faron.com.

 

Forward Looking Statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should", "expect", "hope", "seek", ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

 

A number of factors could cause actual results to differ materially from the results and expectations discussed in the forward-looking statements, many of which are beyond the control of the Company. In particular, the early data from initial patients in the MATINS trial may not be replicated in larger patient numbers and the outcome of clinical trials may not be favourable or clinical trials over and above those currently planned may be required before the Company is able to apply for marketing approval for a product. In addition, other factors which could cause actual results to differ materially include the ability of the Company to successfully licence its programmes within the anticipated timeframe or at all, risks associated with vulnerability to general economic and business conditions, competition, environmental and other regulatory changes, actions by governmental authorities, the availability of capital markets or other sources of funding, reliance on key personnel, uninsured and underinsured losses and other factors. Although any forward-looking statements contained in this announcement are based upon what the Directors believe to be reasonable assumptions, the Company cannot assure investors that actual results will be consistent with such forward looking statements. Accordingly, readers are cautioned not to place undue reliance on forward looking statements. Subject to any continuing obligations under applicable law or any relevant AIM Rule requirements, in providing this information the Company does not undertake any obligation to publicly update or revise any of the forward-looking statements or to advise of any change in events, conditions or circumstances on which any such statement is based.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAFFFLLLDIRLIF
Date   Source Headline
6th Aug 20191:53 pmRNSIssue of Equity
5th Aug 20197:00 amRNSSubscription and Open Offer
12th Jul 20197:00 amRNSMATINS study update
5th Jul 20199:00 amRNSPrice Monitoring Extension
4th Jul 20194:40 pmRNSSecond Price Monitoring Extn
4th Jul 20194:35 pmRNSPrice Monitoring Extension
4th Jul 20192:00 pmRNSPrice Monitoring Extension
4th Jul 20199:31 amRNSHoldings in Company
1st Jul 201912:10 pmRNSGrant of options
26th Jun 20197:00 amRNSPhase II INFORAAA study update
14th Jun 20197:00 amRNSFinal results from YODA study
28th May 201912:27 pmRNSResults of AGM
24th May 20199:32 amRNSAGM update, Board & management changes
22nd May 201912:51 pmRNSGrant of Options
21st May 20199:21 amRNSHolding(s) in Company
16th May 20199:16 amRNSHolding(s) in Company
14th May 20197:01 amRNSHoldings in Company
14th May 20197:00 amRNSShare Subscription and Issue of Equity
7th May 20197:05 amRNSNotice of AGM
7th May 20197:00 amRNSFinal Results for the year ended 31 December 2018
2nd May 20195:20 pmRNSStatement regarding Price Movement
2nd May 20192:05 pmRNSSecond Price Monitoring Extn
2nd May 20192:00 pmRNSPrice Monitoring Extension
29th Apr 20197:00 amRNSResults from the Japanese Phase III study
25th Apr 20194:09 pmRNSHolding(s) in Company
12th Apr 20191:20 pmRNSHolding(s) in Company
11th Apr 20197:00 amRNSFirst expansion cohort for MATINS trial part 2
10th Apr 201911:41 amRNSHolding(s) in Company
5th Apr 20197:00 amRNSNotice of Results
2nd Apr 20199:23 amRNSHoldings in Company
29th Mar 20197:00 amRNSHolding(s) in Company
28th Mar 201912:54 pmRNSResults of the Placing and Subscription
26th Mar 20193:31 pmRNSResult of Placing and Issue Price
26th Mar 20197:00 amRNSProposed Placing to raise approximately EUR 3m
21st Feb 20197:00 amRNSMATINS study update
13th Feb 20198:57 amRNSNew data published by Clinical Cancer Research
19th Dec 20187:00 amRNSTraumakine update - YODA results
14th Dec 201811:20 amRNSFirst patient dosed in phase I/II MATINS study
11th Dec 20184:26 pmRNSHolding(s) in Company
5th Dec 20187:00 amRNSPatient subgroup identified from INTEREST trial
3rd Dec 20187:00 amRNSFaron receives CTA approval for Clevegen
6th Nov 20183:52 pmRNSPDMR Dealings
23rd Oct 201811:05 amRNSSecond Price Monitoring Extn
23rd Oct 201811:00 amRNSPrice Monitoring Extension
23rd Oct 20189:06 amRNSSecond Price Monitoring Extn
23rd Oct 20189:00 amRNSPrice Monitoring Extension
22nd Oct 20183:00 pmRNSINTEREST trial update presented at ESICM
18th Sep 20189:23 amRNSDirector/PDMR Shareholding
17th Sep 20187:00 amRNSFaron announces CTA filing for Clevegen
13th Sep 20187:00 amRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.